AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues

Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.